Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Oct 5:11:1759720X19877994.
doi: 10.1177/1759720X19877994. eCollection 2019.

Update on the safety and efficacy of teriparatide in the treatment of osteoporosis

Salvatore Minisola  1 , Cristiana Cipriani  2 , Giada Della Grotta  2 , Luciano Colangelo  2 , Marco Occhiuto  2 , Piergianni Biondi  2 , Chiara Sonato  2 , Evelina Vigna  2 , Mirella Cilli  2 , Jessica Pepe  2
Affiliations
Review

Update on the safety and efficacy of teriparatide in the treatment of osteoporosis

Salvatore Minisola et al. Ther Adv Musculoskelet Dis. .

Abstract

Following the completion of the Fracture Prevention Trial, teriparatide was approved by the United States Food and Drug Administration and the European Medicine Agency as the first therapeutic anabolic agent for the treatment of postmenopausal women with severe osteoporosis. It subsequently received additional approval for the treatment of osteoporosis in men, and for the treatment of osteoporosis associated with glucocorticoid therapy in men and women at risk of fracture. In this review, we summarize the most important data concerning PTH 1-34 therapy before 2016 in the treatment of osteoporosis, and report some outstanding results published in the last 2 years. New data on safety will also discussed, together with the state of art of nonclassical utilization. Finally, in view of the recent approval of biosimilars, possible future landscapes are discussed.

Keywords: fractures; osteoporosis; safety; teriparatide.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: Prof. S. Minisola served as speaker for Abiogen, Amgen, Bruno Farmaceutici, Diasorin, Eli Lilly, Italfarmaco, Shire. He also served in advisory board of Abiogen, Kyowa Kirin, Pfizer, UCB.

Figures

Figure 1.
Figure 1.
Behavior of biochemical markers of bone formation (serum P1NP) and resorption (serum bCTX) following treatment with teriparatide, abaloparatide, and romosozumab. Redrawn with permission from Minisola et al. bCTX, carboxy-terminal cross-linking telopeptide of type I collagen; P1NP, procollagen type I N-terminal propeptide.
See this image and copyright information in PMC

References

    1. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434–1441. - PubMed
    1. Gallagher JC, Genant HK, Crans GG, et al. Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. J Clin Endocrinol Metab 2005; 90: 1583–1587. - PubMed
    1. Diez-Perez A, Marin F, Eriksen EF, et al. Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: a systematic review and meta-analysis. Bone 2019; 120: 1–8. - PubMed
    1. Kendler DL, Marin F, Zerbini CAF, et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2018; 391: 230–240. - PubMed
    1. Geusens P, Marin F, Kendler DL, et al. Effects of Teriparatide compared with risedronate on the risk of fractures in subgroups of postmenopausal women with severe osteoporosis: the VERO trial. J Bone Miner Res 2018; 33: 783–794. - PubMed

LinkOut - more resources